Intertransverse Process Block for Quality of Recovery Post-Open Hepatectomy
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 25, 2025
Trial Information
Current as of July 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a method called the Intertransverse Process Block (ITPB) to help improve recovery for patients undergoing major liver surgery, known as open hepatectomy. The main goal of the study is to see if this technique can reduce pain and enhance the overall quality of recovery in patients after their surgery. Researchers will measure how well patients feel 15 different aspects of their recovery, such as comfort and physical ability, at 24 and 48 hours after the procedure. They will also look at other factors like pain levels, the amount of pain medication needed, and how long it takes for patients to be ready to leave the hospital.
To participate in this trial, adults aged 18 to 75 years who are having open hepatectomy for liver issues may be eligible, provided they have a certain level of health (ASA I to III). However, those who refuse to take part, have infections, bleeding disorders, or are allergic to local anesthetics won't be able to join. While the study is not currently recruiting participants, it aims to gather important information on how the ITPB may help enhance recovery for individuals undergoing this type of surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Adult patients aged 18-75 years of ASA I - III physical status classification undergoing open hepatectomy for benign or malignant liver lesion.
- Exclusion Criteria:
- • Patient refusal
- • Patients who are unable to comprehend the QoR15 form
- • Local or systemic infection
- • Coagulopathy leading to absolute contraindication to regional anesthesia
- • Contraindication to local anaesthetics (LA) such as LA allergy
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported